Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo targets tough cancers in early trial

NCT ID NCT04913285

Disease control Sponsor: Pierre Fabre Medicament Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Sep 03, 2026 · Updated 3 times

Summary

This early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. The study is active but no longer recruiting new participants.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
KIN-2787 (exarafenib) and binimetinib
What this could lead to
If successful, this could lead to a new treatment option for people with certain hard-to-treat cancers like melanoma and lung cancer that have specific genetic mutations.
What could go wrong
This is an early phase 1 trial, so the drug may not work or could have serious side effects. It is still being tested for safety and the right dose, so it is far from being a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2021

Expected to finish

Mar 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Provide written informed consent prior to initiation of any study-specific procedures. * Metastatic or advanced stage solid tumor * Known BRAF Class I, Class II, or Class III alteration or melanoma with an NRAS mutation as confirmed by previous genomic analysis of tumor tissue or ctDNA. * Measurable (Part A and B) or evaluable (Part A only) disease by RECIST v1.1. * ECOG performance status 0-1 * Adequate organ function, as measured by laboratory values (criteria listed in protocol). * Able to swallow, retain, and absorb oral medications. Exclusion Criteria: * Known participants who have received local therapy with either surgery and/or radiation therapy (participants with asymptomatic untreated brain metastasis may be eligible if met with certain criteria) * In Part B Dose Expansion, previous treatment with any approved or in-development small molecule BRAF-, MEK-, or MAPK-directed inhibitor therapy. * GI tract disease causing an inability to take oral medication, malabsorption syndrome, requirement for intravenous alimentation, or uncontrolled inflammatory GI disease. * Active, uncontrolled bacterial, fungal, or viral infection. * Participant with a positive test result for SARS-CoV2 infection, is known to have asymptomatic infection or is suspected of having SARS-CoV2, is excluded * Women who are lactating or breastfeeding, or pregnant. * Participants with any other active treated malignancy within 3 years prior to enrollment Complete inclusion and exclusion criteria are listed in the clinical study protocol.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Melanoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

melanoma Neoplasm Metastasis non-small cell lung carcinoma thyroid gland disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Melanoma Non-small cell lung cancer Solid tumor, adult

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    44 sites in 6 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHM-CHU La Timone

    RECRUITING

    Marseille, France

  • APHP - Hôpital St Louis

    RECRUITING

    Paris, France

  • Arance

    RECRUITING

    Barcelona, Spain, Spain

  • Atlantic Health

    RECRUITING

    Morristown, New Jersey, 07960, United States

  • Austin Health

    RECRUITING

    Heidelberg, Victoria, 3084, Australia

  • Beijing University Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Beijing, 100142, China

  • Berrocal

    RECRUITING

    Valencia, Spain, Spain

  • CHU Nantes-Hotel Dieu

    RECRUITING

    Nantes, France

  • CHU de Lille

    RECRUITING

    Lille, France

  • CHU de Nice - Hôpital Archet 2

    RECRUITING

    Nice, France

  • CHU de Poitiers

    RECRUITING

    Poitiers, France

  • Calvary Mater Hospital Newcastle

    RECRUITING

    Waratah, New South Wales, 2298, Australia

  • Centre Francois Baclesse

    RECRUITING

    Caen, France

  • Centre Leon Berard

    RECRUITING

    Lyon, France

  • Cleveland Clinic

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Gustave Roussy

    RECRUITING

    Villejuif, 94805, France

  • H. Regional de Málaga

    RECRUITING

    Málaga, Spain, Spain

  • H. Virgen Macarena

    RECRUITING

    Seville, Spain, Spain

  • Harbin Medical University Cancer Hospital

    RECRUITING

    Haerbin, Heilongjiang, 150081, China

  • Hospices Civiles de Lyon - Hôpital Lyon Sud

    RECRUITING

    Pierre-Bénite, France

  • Hospital General Gregorio Marañón

    RECRUITING

    Madrid, 29009, Spain

  • Hospital Quiron Dexeus

    RECRUITING

    Barcelona, Spain

  • Hospital Universitario Insular de Gran Canaria

    RECRUITING

    Las Palmas de Gran Canaria, Spain

  • INCLIVA (Hospital Clinico de Valencia)

    RECRUITING

    Valencia, Spain

  • Institut Bergonie

    RECRUITING

    Bordeaux, France

  • Istituto Nazionale dei Tumori Fondazione G. Pascale

    RECRUITING

    Naples, 80131, Italy

  • Linear Clinical Research

    RECRUITING

    Perth, Western Australia, 6009, Australia

    Contact Email: •••••@•••••

  • Linyi Cancer Hospital

    ACTIVE_NOT_RECRUITING

    Linyi, Shandong, 276001, China

  • MD Anderson

    NOT_YET_RECRUITING

    Houston, Texas, 77030, United States

  • Mayo Clinic - Florida

    RECRUITING

    Jacksonville, Florida, 32224, United States

  • Mayo Clinic - Rochester

    RECRUITING

    Rochester, Minnesota, 55905, United States

  • Melanoma Institute Australia

    RECRUITING

    Wollstonecraft, New South Wales, 2065, Australia

  • NEXT Quirónsalud Madrid

    RECRUITING

    Madrid, Spain, Spain

  • NYU Langone

    RECRUITING

    New York, New York, 10016, United States

  • National Taiwan University Hospital

    ACTIVE_NOT_RECRUITING

    Taipei, Taiwan

  • Oncopole Claudius Regaud

    RECRUITING

    Toulouse, 31059, France

  • Rutgers Cancer Institute of New Jersey

    RECRUITING

    New Brunswick, New Jersey, 08901, United States

  • START Madrid

    RECRUITING

    Madrid, 28050, Spain

  • Sarah Cannon Research Institute - Florida Cancer Specialists

    RECRUITING

    Orlando, Florida, 32827, United States

  • Sarah Cannon Research Institute Denver

    RECRUITING

    Denver, Colorado, 80218-1238, United States

  • Sarah Cannon Research Institute-Tennessee Oncology

    RECRUITING

    Nashville, Tennessee, 37203, United States

  • Tasman Health Care

    RECRUITING

    Southport, Queensland, 4215, Australia

  • The Angeles Clinic

    RECRUITING

    Los Angeles, California, 90025-6602, United States

  • The Shanghai Pulmonary Hospital

    ACTIVE_NOT_RECRUITING

    Shanghai, 200433, China

  • UCLA

    RECRUITING

    Los Angeles, California, 90095, United States

  • University of California San Diego, Moores Cancer Center

    RECRUITING

    San Diego, California, 92093, United States

  • University of California San Francisco

    RECRUITING

    San Francisco, California, 94143-2205, United States

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22031, United States

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.